Merck & Co (NYSE: MRK) has secured another approval from the US Food and Drug Administration for its blockbuster immuno-oncology product, Keytruda (pembrolizumab).
The anti-PD-1 therapy has been approved, in combination with gemcitabine and cisplatin, for the treatment of certain people with biliary tract cancer.
Cancers of this kind can be more aggressive, and there remains a high level of unmet medical need, with more people being diagnosed every year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze